


Myeloid/lymphoid neoplasm with FGFR1 rearrangement

Sharon Koorse Germans and Mingyi Chen, University of Texas Southwestern



A 25-year-old man presented with a leukocyte count of $174 \times 10^9/L$, massive splenomegaly, inguinal lymphadenopathy, night sweats, weight loss, and early satiety for 1 month. The peripheral blood smear revealed marked absolute left-shifted neutrophilia, eosinophilia, and basophilia with flow cytometric detection of 1.3% aberrant myeloblasts and 0.01% immature T cells by minimal residual disease analysis (panel B, inset). The inguinal lymph node biopsy showed diffuse sheets of medium lymphoid cells that stained positive for CD1a and terminal deoxynucleotidyl-transferase (panel A, hematoxylin and eosin (H&E) stain, original magnification $\times 400$; inset, original magnification $\times 100$). The concurrent flow cytometry analysis confirmed involvement by T-lymphoblastic leukemia/lymphoma. The bone marrow examination showed a hypercellular marrow with left-shifted myeloid and megakaryocytic hyperplasia, with 1% blasts (panel B, H&E stain,

original magnification $\times 100$). An FGFR1 (8p11) gene rearrangement was detected in the lymph node (85% of cells) and bone marrow (95% of cells) (panel C; break apart FISH with red-3¹FGFR1, green-5¹ FGFR1, and yellow fusion signals) by fluorescence in situ hybridization analysis and was negative for BCR-ABL1. Cytogenetics revealed t(8;13) in the bone marrow (panel D).

This is a rare case of an 8p11 myeloproliferative neoplasm that harbors stem cell properties and can present as a bilineage/trilineage neoplasm. There is no definite established remission-induction regimen, and the myeloid neoplasms exhibit chemoresistance to first- and second-generation tyrosine kinase inhibitors (TKIs). Newer TKIs and small molecule FGFR1 inhibitors (pemigatinib; clinical trial FIGHT-203) may be effective bridging therapies to stem cell transplant.